je.st
news
Tag: antagonist
Mercks Insomnia Medicine BELSOMRA (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States
2015-02-03 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that BELSOMRA (suvorexant) is now available at pharmacies in the United States for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep. BELSOMRA is the only orexin receptor antagonist approved for the treatment of insomnia in the United States. Orexin is one of the many neurotransmitters in the brain involved in promoting wakefulness, and BELSOMRA selectively blocks orexin receptors. Language: English Contact: Merck & Co., Inc.Media:Pam Eisele, 267-305-3558orMegan Wilkinson, 267-305-6463orInvestor:Justin Holko, 908-740-1879orJoe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
united
states
medicine
Germany Emerges as Net Neutrality Antagonist
2014-12-11 13:47:17| Telecom - Topix.net
It is opening another front in the growing battle between Europe and the U.S. on control over the Internet, and toward what some warn is an increasing balkanization of the World Wide Web. In November, President Barack Obama called on the Federal Communications Commission to declare broadband Internet service a public utility, saying that it is essential to the economy and that the "strongest possible rules" are needed to ensure that the Internet doesn't become divided into fast and slow lanes.
Tags: net
germany
emerges
antagonist
FDA Approves ZONTIVITY (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
2014-05-12 13:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. ZONTIVITY Added to Standard of Care Demonstrated Long-Term Benefit Through Three Years WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZONTIVITY (vorapaxar) for the reduction of thrombotic cardiovascular events in patients with a history of heart attack (myocardial infarction) or in patients with narrowing of leg arteries, called peripheral arterial disease (PAD). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orPatrick Witmer, 267-305-4910orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [1]